SINGAPORE/BANGALORE - A Singapore-based company is at the centre of a Brazil government probe into alleged irregularities over the South American country's deal to purchase India's indigenous Covid-19 vaccine Covaxin.
With the world's highest death toll from Covid-19 after the United States, Brazil desperately needs vaccines, but on June 29, it cancelled its US$320 million (S$433 million) February contract with Indian vaccine maker Bharat Biotech over allegations of corruption in the deal. The company was to supply 20 million doses of Covaxin, developed with Indian government support.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
